Literature DB >> 1382896

Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients.

U Christians1, F Braun, M Schmidt, N Kosian, H M Schiebel, L Ernst, M Winkler, C Kruse, A Linck, K F Sewing.   

Abstract

A specific and sensitive assay for quantifying the immunosuppressant FK506 and its metabolites in blood and urine was developed. 32-O-Acetyl FK506 was synthesized and used as internal standard. FK506 and its metabolites were purified from the samples by solid-liquid extraction and were injected into a high-performance liquid chromatographic (HPLC) system linked to a mass spectrometer (MS) by particle-beam interface. The FK506 derivatives were separated from interfering material by use of a 100 x 4 mm C8 analytical column and water/acetonitrile or water/methanol gradient elution; they were detected by negative chemical ionization with methane as reagent gas. The limit of detection was 25 pg in a standard solution, and the limit of quantification in blood was 250 pg (extracted from 1 mL of blood). The CV was 11.3% at 5 ng, and no interferences with other drugs were found.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382896

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  14 in total

1.  FK506 measurement: comparison of different analytical methods.

Authors:  V Warty; S Zuckerman; R Venkataramanan; J Lever; J Fung; T Starzl
Journal:  Ther Drug Monit       Date:  1993-06       Impact factor: 3.681

Review 2.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 3.  Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Authors:  P E Wallemacq; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  A risk-benefit assessment of tacrolimus in transplantation.

Authors:  M Winkler; U Christians
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

6.  Tacrolimus analysis: a comparison of different methods and matrices.

Authors:  V Warty; S Zuckerman; R Venkataramanan; J Lever; J Chao; T Mckaveney; J Fung; T Starzl
Journal:  Ther Drug Monit       Date:  1995-04       Impact factor: 3.681

Review 7.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

9.  Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA).

Authors:  A K Gonschior; U Christians; F Braun; M Winkler; A Linck; J Baumann; K F Sewing
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

10.  Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber.

Authors:  A Lampen; U Christians; A K Gonschior; A Bader; I Hackbarth; W von Engelhardt; K F Sewing
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.